Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis

Conclusion: The PK of DAC HYP in patients with RRMS are consistent with those previously reported in healthy volunteers. The half-life of ~3 weeks and the low fluctuations in peak and trough concentrations of serum DAC HYP support the once-monthly SC dosing regimen. Keywords: pharmacokinetics, daclizumab high-yield process, multiple sclerosis
Source: International Journal of COPD - Category: Respiratory Medicine Tags: Clinical Pharmacology: Advances and Applications Source Type: research